- Status:
- Topic selection
- Technology type:
- Medicine
- Decision:
- Not selected
- Reason for decision:
- Not eligible for Health Technology Evaluation guidance
- Further information:
- The 2024 voluntary scheme for branded medicines, pricing, access and growth states that NICE will continue to evaluate all new active substances and significant indications, except where there is a clear rationale not to do so. Decision makers have concluded that the clear rationale to not evaluate this product is due to Zanubrutinib being a new formulation of existing guidance TA833, TA1001, TA931 and ID6392. Therefore, there would be no additional value in conducting a separate evaluation. Please see eligibility criteria within the prioritisation manual for further information.
- ID number:
- 12199
Project Team
- Project lead
- Danielle Lees
Email enquiries
If you have any queries please email [email protected]
Related links
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 16 May 2025 | Topic selection |
For further information on how we select topics for development, please see our page about prioritising our guidance topics